These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28873466)

  • 1. Rational design of drug-like compounds targeting Mycobacterium marinum MelF protein.
    Dharra R; Talwar S; Singh Y; Gupta R; Cirillo JD; Pandey AK; Kulharia M; Mehta PK
    PLoS One; 2017; 12(9):e0183060. PubMed ID: 28873466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Mycobacterium marinum mel2 locus displays similarity to bacterial bioluminescence systems and plays a role in defense against reactive oxygen and nitrogen species.
    Subbian S; Mehta PK; Cirillo SL; Cirillo JD
    BMC Microbiol; 2007 Jan; 7():4. PubMed ID: 17239244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Mycobacterium marinum mel2 mutant is defective for growth in macrophages that produce reactive oxygen and reactive nitrogen species.
    Subbian S; Mehta PK; Cirillo SL; Bermudez LE; Cirillo JD
    Infect Immun; 2007 Jan; 75(1):127-34. PubMed ID: 17030568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of in silico designed inhibitors targeting MelF (Rv1936) against Mycobacterium marinum within macrophages.
    Dharra R; Radhakrishnan VS; Prasad T; Thakur Z; Cirillo JD; Sheoran A; Pandey AK; Kulharia M; Mehta PK
    Sci Rep; 2019 Jul; 9(1):10084. PubMed ID: 31300732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Could mycobacterial MelF protein (Rv1936) be used as a potential drug target?
    Mehta PK; Dharra R; Kulharia M
    Future Microbiol; 2018 Sep; 13():1211-1214. PubMed ID: 30238773
    [No Abstract]   [Full Text] [Related]  

  • 7. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
    Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
    Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
    Rani C; Mehra R; Sharma R; Chib R; Wazir P; Nargotra A; Khan IA
    Tuberculosis (Edinb); 2015 Dec; 95(6):664-677. PubMed ID: 26318557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis.
    Matviiuk T; Madacki J; Mori G; Orena BS; Menendez C; Kysil A; André-Barrès C; Rodriguez F; Korduláková J; Mallet-Ladeira S; Voitenko Z; Pasca MR; Lherbet C; Baltas M
    Eur J Med Chem; 2016 Nov; 123():462-475. PubMed ID: 27490025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Mycobacterium marinum zone of inhibition assay as a method for screening potential antimycobacterial compounds from marine extracts.
    Barker LP; Lien BA; Brun OS; Schaak DD; McDonough KA; Chang LC
    Planta Med; 2007 Jun; 73(6):559-63. PubMed ID: 17534789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Mycobacterium tuberculosis α-1,4-glucan branching enzyme (GlgB) inhibitors by structure- and ligand-based virtual screening.
    Dkhar HK; Gopalsamy A; Loharch S; Kaur A; Bhutani I; Saminathan K; Bhagyaraj E; Chandra V; Swaminathan K; Agrawal P; Parkesh R; Gupta P
    J Biol Chem; 2015 Jan; 290(1):76-89. PubMed ID: 25384979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of Natural Growth of Two Strains of Mycobacterium Marinum for Translational Antituberculosis Drug Development.
    Van Wijk RC; van der Sar AM; Krekels EHJ; Verboom T; Spaink HP; Simonsson USH; van der Graaf PH
    Clin Transl Sci; 2020 Nov; 13(6):1060-1064. PubMed ID: 32267997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of anti-mycobacterial compounds in a naturally infected zebrafish larvae model.
    Dalton JP; Uy B; Okuda KS; Hall CJ; Denny WA; Crosier PS; Swift S; Wiles S
    J Antimicrob Chemother; 2017 Feb; 72(2):421-427. PubMed ID: 27798206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
    Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.
    Malapati P; Krishna VS; Nallangi R; Srilakshmi RR; Sriram D
    Eur J Med Chem; 2018 Feb; 145():23-34. PubMed ID: 29310027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetate Kinase (AcK) is Essential for Microbial Growth and Betel-derived Compounds Potentially Target AcK, PhoP and MDR Proteins in M. tuberculosis, V. cholerae and Pathogenic E. coli: An in silico and in vitro Study.
    Tiwari S; Barh D; Imchen M; Rao E; Kumavath RK; Seenivasan SP; Jaiswal AK; Jamal SB; Kumar V; Ghosh P; Azevedo V
    Curr Top Med Chem; 2018; 18(31):2731-2740. PubMed ID: 30663567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Silico Driven Design and Synthesis of Rhodanine Derivatives as Novel Antibacterials Targeting the Enoyl Reductase InhA.
    Slepikas L; Chiriano G; Perozzo R; Tardy S; Kranjc A; Patthey-Vuadens O; Ouertatani-Sakouhi H; Kicka S; Harrison CF; Scrignari T; Perron K; Hilbi H; Soldati T; Cosson P; Tarasevicius E; Scapozza L
    J Med Chem; 2016 Dec; 59(24):10917-10928. PubMed ID: 26730986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophostin and Cyclipostins analogues, new promising molecules to treat mycobacterial-related diseases.
    Nguyen PC; Madani A; Santucci P; Martin BP; Paudel RR; Delattre S; Herrmann JL; Spilling CD; Kremer L; Canaan S; Cavalier JF
    Int J Antimicrob Agents; 2018 Apr; 51(4):651-654. PubMed ID: 29241819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase.
    Shukla R; Shukla H; Sonkar A; Pandey T; Tripathi T
    J Biomol Struct Dyn; 2018 Jun; 36(8):2045-2057. PubMed ID: 28605994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhance the Antimycobacterial Activity of Streptomycin with Ebselen as an Antibiotic Adjuvant Through Disrupting Redox Homeostasis.
    Dong C; Wang Y; Cai Y; Wu Y; Chen W; Wang L; Liu X; Zou L; Wang J
    Drug Des Devel Ther; 2024; 18():3811-3824. PubMed ID: 39219694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.